Publications by authors named "H-J Busse"
Article Synopsis
- * Results showed that both doses of sebetralstat provided significantly quicker relief from symptoms and attack severity compared to the placebo, with median times to relief around 1.6-1.8 hours versus over 6 hours for placebo.
- * The trial included 136 participants who treated 264 attacks, demonstrating that sebetralstat could potentially offer a more convenient oral alternative to current parenteral treatments for hereditary angioedema.
The prognosis of chronic lymphocytic leukemia (CLL) depends on different markers, including cytogenetic aberrations, oncogenic mutations, and mutational status of the immunoglobulin (Ig) heavy-chain variable (IGHV) gene. The number of IGHV mutations distinguishes mutated (M) CLL with a markedly superior prognosis from unmutated (UM) CLL cases. In addition, B cell antigen receptor (BCR) stereotypes as defined by IGHV usage and complementarity-determining regions (CDRs) classify ∼30% of CLL cases into prognostically important subsets.
View Article and Find Full Text PDFBackground: Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) is a new kallikrein inhibitor with the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency.
Methods: We conducted a phase 1b, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial.